All Stories

  1. Adenovirus type 5 vectors encoding short hairpin RNAs targeting dengue virus 5’ non-translated region and capsid gene suppress pre-established dengue infection in cultured epithelial and myeloid cells

    Article • Virus Research, October 2021, Elsevier

    Sathyamangalam Swaminathan

  2. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models

    Article • EBioMedicine, October 2020, Elsevier

    Sathyamangalam Swaminathan

  3. The RNA secondary structural variation in the cyclization elements of the dengue genome and the possible implications in pathogenicity

    Article • VirusDisease, July 2020, Springer Science + Business Media

    Sathyamangalam Swaminathan

  4. Tetravalent Dengue Vaccine in Healthy Children

    Article • New England Journal of Medicine, April 2020, New England Journal of Medicine (NEJM/MMS)

    Sathyamangalam Swaminathan

  5. Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement

    Article • EBioMedicine, April 2020, Elsevier

    Sathyamangalam Swaminathan

  6. Pichia pastoris-expressed Zika virus envelope domain III on a virus-like particle platform: design, production and immunological evaluation

    Article • Pathogens and Disease, April 2019, Oxford University Press (OUP)

    Sathyamangalam Swaminathan

  7. Next generation designer virus-like particle vaccines for dengue

    Article • Expert Review of Vaccines, January 2019, Taylor & Francis

    Sathyamangalam Swaminathan

  8. Dengue Vaccine Development: Global and Indian Scenarios

    Article • International Journal of Infectious Diseases, January 2019, Elsevier

    Sathyamangalam Swaminathan

  9. Dengue envelope-based ‘four-in-one’ virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice

    Article • Scientific Reports, June 2018, Springer Science + Business Media

    Sathyamangalam Swaminathan

  10. Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo

    Article • Frontiers in Microbiology, January 2018, Frontiers

    Sathyamangalam Swaminathan

  11. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice

    Article • PLoS Neglected Tropical Diseases, January 2018, PLOS

    Sathyamangalam Swaminathan

  12. A quinoline compound inhibits the replication of dengue virus serotypes 1–4 in Vero cells

    Article • Antiviral Therapy, January 2018, International Medical Press

    Sathyamangalam Swaminathan

  13. Electrospun manganese (III) oxide nanofiber based electrochemical DNA-nanobiosensor for zeptomolar detection of dengue consensus primer

    Article • Biosensors and Bioelectronics, April 2017, Elsevier

    Sathyamangalam Swaminathan

  14. Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies

    Article • American Journal of Tropical Medicine and Hygiene, November 2016, American Society of Tropical Medicine and Hygiene

    Sathyamangalam Swaminathan

  15. Investigational drugs in early development for treating dengue infection

    Article • Expert Opinion on Investigational Drugs, June 2016, Taylor & Francis

    Sathyamangalam Swaminathan

  16. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies

    Article • BMC Biotechnology, June 2016, Springer Science + Business Media

    Sathyamangalam Swaminathan

  17. Cissampelos pareira Linn: Natural Source of Potent Antiviral Activity against All Four Dengue Virus Serotypes

    Article • PLoS Neglected Tropical Diseases, December 2015, PLOS

    Sathyamangalam Swaminathan

  18. Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies

    Article • Frontiers in Microbiology, September 2015, Frontiers

    Sathyamangalam Swaminathan

  19. A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture

    Article • Virology Journal, January 2015, Springer Science + Business Media

    Sathyamangalam Swaminathan

  20. Drugs for dengue: a patent review (2010 – 2014)

    Article • Expert Opinion on Therapeutic Patents, October 2014, Informa Healthcare

    Sathyamangalam Swaminathan

  21. Diagnostic Potential and Antigenic Properties of Recombinant Tick-Borne Encephalitis Virus Subviral Particles Expressed in Mammalian Cells from Semliki Forest Virus Replicons

    Article • Journal of Clinical Microbiology, December 2013, ASM Journals

    Sathyamangalam Swaminathan

  22. Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing Antibodies

    Article • PLoS ONE, May 2013, PLOS

    Sathyamangalam Swaminathan

  23. Dengue vaccine efficacy trial: does interference cause failure?

    Article • The Lancet Infectious Diseases, March 2013, Elsevier

    Sathyamangalam Swaminathan

  24. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice

    Article • Vaccine, January 2013, Elsevier

    Sathyamangalam Swaminathan

  25. Experimental Dengue Vaccines

    Article • January 2013, Springer Science + Business Media

    Sathyamangalam Swaminathan

  26. Dengue-specific subviral nanoparticles: design, creation and characterization

    Article • Journal of Nanobiotechnology, January 2013, Springer Science + Business Media

    Sathyamangalam Swaminathan

  27. Escherichia coli–expressed near full length HIV-1 envelope glycoprotein is a highly sensitive and specific diagnostic antigen

    Article • BMC Infectious Diseases, November 2012, Springer Science + Business Media

    Sathyamangalam Swaminathan

  28. Adenovirus Delivered Short Hairpin RNA Targeting a Conserved Site in the 5′ Non-Translated Region Inhibits All Four Serotypes of Dengue Viruses

    Article • PLoS Neglected Tropical Diseases, July 2012, PLOS

    Sathyamangalam Swaminathan

  29. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2

    Article • Journal of Nanobiotechnology, January 2012, Springer Science + Business Media

    Sathyamangalam Swaminathan

  30. A highly sensitive and specific time resolved fluorometric bridge assay for antibodies to HIV-1 and -2

    Article • Journal of Virological Methods, April 2011, Elsevier

    Sathyamangalam Swaminathan

  31. Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera

    Article • BMC Infectious Diseases, March 2011, Springer Science + Business Media

    Sathyamangalam Swaminathan

  32. Expression, purification and characterization of in vivo biotinylated dengue virus envelope domain III based tetravalent antigen

    Article • Protein Expression and Purification, November 2010, Elsevier

    Sathyamangalam Swaminathan

  33. Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris

    Article • Journal of Bioscience and Bioengineering, October 2010, Elsevier

    Sathyamangalam Swaminathan

  34. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies

    Article • Journal of Virological Methods, July 2010, Elsevier

    Sathyamangalam Swaminathan

  35. Dengue vaccines: state of the art

    Article • Expert Opinion on Therapeutic Patents, April 2010, Informa Healthcare

    Sathyamangalam Swaminathan

  36. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines

    Article • Journal of Medical Virology, March 2010, Wiley

    Sathyamangalam Swaminathan

  37. Inexpensive Designer Antigen for Anti-HIV Antibody Detection with High Sensitivity and Specificity

    Article • Clinical and Vaccine Immunology, January 2010, ASM Journals

    Sathyamangalam Swaminathan

  38. Simultaneous detection of Human Immunodeficiency Virus 1 and Hepatitis B virus infections using a dual-label time-resolved fluorometric assay

    Article • Journal of Nanobiotechnology, January 2010, Springer Science + Business Media

    Sathyamangalam Swaminathan

  39. Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin

    Article • Microbial Cell Factories, January 2010, Springer Science + Business Media

    Sathyamangalam Swaminathan

  40. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity

    Article • Vaccine, October 2009, Elsevier

    Sathyamangalam Swaminathan

  41. Dengue: Recent Advances in Biology and Current Status of Translational Research

    Article • Current Molecular Medicine, March 2009, Bentham Science Publishers

    Sathyamangalam Swaminathan

  42. Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen

    Article • Microbial Cell Factories, January 2009, Springer Science + Business Media

    Sathyamangalam Swaminathan

  43. Adenovirus-vectored vaccines

    Article • Expert Opinion on Therapeutic Patents, March 2008, Informa Healthcare

    Sathyamangalam Swaminathan

  44. Single Antigen Detects both Immunoglobulin M (IgM) and IgG Antibodies Elicited by All Four Dengue Virus Serotypes

    Article • Clinical and Vaccine Immunology, September 2007, ASM Journals

    Sathyamangalam Swaminathan

  45. Article • BMC Biotechnology, January 2007, Springer Science + Business Media

    Sathyamangalam Swaminathan

  46. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors

    Article • Vaccine, October 2006, Elsevier

    Sathyamangalam Swaminathan

  47. Major Antifungal Activity from the Bulbs of Indian Squill Urginea indica Is a Chitinase

    Article • Biotechnology Progress, June 2006, Wiley

    Sathyamangalam Swaminathan

  48. A synthetic dengue virus antigen elicits enhanced antibody titers when linked to, but not mixed with, Mycobacterium tuberculosis HSP70 domain II

    Article • Vaccine, May 2006, Elsevier

    Sathyamangalam Swaminathan

  49. Recombinant Multiepitope Protein for Early Detection of Dengue Infections

    Article • Clinical and Vaccine Immunology, January 2006, ASM Journals

    Sathyamangalam Swaminathan

  50. The identification of immunodominant linear epitopes of dengue type 2 virus capsid and NS4a proteins using pin-bound peptides

    Article • Virus Research, September 2005, Elsevier

    Sathyamangalam Swaminathan

  51. A custom-designed recombinant multiepitope protein as a dengue diagnostic reagent

    Article • Protein Expression and Purification, May 2005, Elsevier

    Sathyamangalam Swaminathan

  52. High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli

    Article • Protein Expression and Purification, January 2004, Elsevier

    Sathyamangalam Swaminathan

  53. Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2

    Article • Journal of Virology, December 2003, ASM Journals

    Sathyamangalam Swaminathan

  54. Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen

    Article • Journal of Biotechnology, October 2002, Elsevier

    Sathyamangalam Swaminathan

  55. Expression and Purification of Dengue Virus Type 2 Envelope Protein as a Fusion with Hepatitis B Surface Antigen in Pichia pastoris

    Article • Protein Expression and Purification, October 2001, Elsevier

    Sathyamangalam Swaminathan

  56. Expression of hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris using the GAP promoter

    Article • Journal of Biotechnology, June 2001, Elsevier

    Sathyamangalam Swaminathan

  57. Effect of Copy Number on the Expression Levels of Hepatitis B Surface Antigen in the Methylotrophic Yeast Pichia pastoris

    Article • Protein Expression and Purification, February 2001, Elsevier

    Sathyamangalam Swaminathan

  58. p300/cAMP-responsive Element-binding Protein Interactions with Ets-1 and Ets-2 in the Transcriptional Activation of the Human Stromelysin Promoter

    Article • Journal of Biological Chemistry, June 1999, American Society for Biochemistry & Molecular Biology (ASBMB)

    Sathyamangalam Swaminathan

  59. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer

    Article • Gene Therapy, May 1999, Nature

    Sathyamangalam Swaminathan

  60. Affinity Purification of Recombinant Interferon-α on a Mimetic Ligand Adsorbent

    Article • Protein Expression and Purification, March 1999, Elsevier

    Sathyamangalam Swaminathan

  61. Regulation of Cellular Genes in a Chromosomal Context by the Retinoblastoma Tumor Suppressor Protein

    Article • Molecular and Cellular Biology, August 1998, ASM Journals

    Sathyamangalam Swaminathan

  62. Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein

    Article • The EMBO Journal, January 1997, Wiley

    Sathyamangalam Swaminathan

  63. Simian Virus 40 Large-T Bypasses the Translational Block Imposed by the Phosphorylation of eIF-2α

    Article • Virology, May 1996, Elsevier

    Sathyamangalam Swaminathan

  64. Transactivation of Adenovirus E2-early Promoter by E1A and E4 6/7 in the Context of Viral Chromosome

    Article • Journal of Molecular Biology, May 1996, Elsevier

    Sathyamangalam Swaminathan

  65. Translation Control by Adenovirus Virus-Associated RNA I

    Article • January 1993, Springer Science + Business Media

    Sathyamangalam Swaminathan

  66. Activation of a dual adenovirus promoter containing nonconsensus TATA motifs inSchizosaccharomyces pombe: role of TATA sequences in the efficiency of transcription

    Article • Nucleic Acids Research, January 1993, Oxford University Press (OUP)

    Sathyamangalam Swaminathan